Neurogene Inc. (NGNE) Ownership
NGNE ownership summary
as of October 18, 2026- Institutions
- 97.6% of shares outstanding
- Insiders
- 6.98% of shares outstanding
- Shares outstanding
- 20.0M
- Float
- 11.3M shares available to trade
- Short interest
- 29.50% 5.0M shares short
- Days to cover
- 16.10 short interest up 51.7% vs prior month
- Institutions 97.60%
- Insiders 6.98%
NGNE top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Samsara BioCapital, LLC | 8.58% | 1.7M | $39.9M | — | June 30, 2026 |
| 2 | Casdin Capital, LLC | 7.72% | 1.5M | $35.9M | +125,000 (+8.8%) | June 30, 2026 |
| 3 | Redmile Group, LLC | 7.06% | 1.4M | $32.8M | −47,400 (−3.2%) | June 30, 2026 |
| 4 | RTW INVESTMENTS, LLC | 6.81% | 1.4M | $31.7M | — | June 30, 2026 |
| 5 | EcoR1 Capital, LLC | 6.35% | 1.3M | $29.6M | — | June 30, 2026 |
| 6 | BlackRock Inc | 5.29% | 1.1M | $24.6M | +52,913 (+5.3%) | June 30, 2026 |
| 7 | Baker Bros Advisors LP | 4.96% | 992K | $23.1M | — | June 30, 2026 |
| 8 | Balyasny Asset Management LLC | 4.09% | 819K | $19.0M | +100,317 (+14.0%) | June 30, 2026 |
| 9 | Trails Edge Capital Partners, LP | 3.57% | 715K | $16.6M | −67,902 (−8.7%) | June 30, 2026 |
| 10 | The Toronto-Dominion Bank | 3.40% | 681K | $15.8M | — | June 30, 2026 |
| 11 | Vanguard Capital Management, LLC | 2.68% | 537K | $12.5M | +21,798 (+4.2%) | June 30, 2026 |
| 12 | Jennison Associates LLC | 2.59% | 519K | $12.1M | −9,103 (−1.7%) | June 30, 2026 |
| 13 | Citadel Advisors Llc | 2.04% | 409K | $9.5M | +21,951 (+5.7%) | June 30, 2026 |
| 14 | Great Point Partners LLC | 1.76% | 352K | $8.2M | −147,820 (−29.6%) | June 30, 2026 |
| 15 | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 1.71% | 342K | $8.0M | −182,343 (−34.7%) | June 30, 2026 |
| 16 | FMR Inc | 1.48% | 296K | $6.9M | −87,086 (−22.8%) | June 30, 2026 |
| 17 | Geode Capital Management, LLC | 1.47% | 293K | $6.8M | +14,179 (+5.1%) | June 30, 2026 |
| 18 | State Street Corp | 1.12% | 224K | $5.2M | −88,683 (−28.3%) | June 30, 2026 |
| 19 | Franklin Templeton Inc | 1.02% | 204K | $4.7M | +204,280 (0.0%) | June 30, 2026 |
| 20 | Morgan Stanley - Brokerage Accounts | 0.96% | 192K | $4.5M | −93,515 (−32.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 7 holders added 540K shares and 8 cut 724K.
NGNE top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.60% | 521K | $12.1M | — | August 31, 2026 |
| 2 | Franklin Biotechnology Discv A(acc)USD | 2.05% | 409K | $9.5M | — | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 2.02% | 404K | $9.4M | −4,672 (−1.1%) | September 30, 2026 |
| 4 | State Street® SPDR® S&P® Biotech ETF | 1.34% | 269K | $6.2M | −5,150 (−1.9%) | September 30, 2026 |
| 5 | T. Rowe Price Small-Cap Stock | 1.32% | 265K | $6.2M | −176 (−0.1%) | August 31, 2026 |
| 6 | Franklin Biotechnology Discovery A | 1.09% | 219K | $5.1M | — | August 31, 2026 |
| 7 | Fidelity Advisor Biotechnology I | 0.89% | 177K | $4.1M | — | August 31, 2026 |
| 8 | iShares Russell 2000 Value ETF | 0.73% | 147K | $3.4M | +222 (+0.2%) | September 30, 2026 |
| 9 | T. Rowe Price Instl Small-Cap Stock | 0.72% | 143K | $3.3M | — | August 31, 2026 |
| 10 | T. Rowe Price Small-Cap Value | 0.66% | 131K | $3.1M | −1,205 (−0.9%) | August 31, 2026 |
| 11 | PGIM Jennison Health Sciences Z | 0.63% | 126K | $2.9M | — | August 31, 2026 |
| 12 | iShares Biotechnology ETF | 0.62% | 124K | $2.9M | −944 (−0.8%) | September 30, 2026 |
| 13 | Fidelity Small Cap Index | 0.62% | 124K | $2.9M | +1,298 (+1.1%) | July 31, 2026 |
| 14 | Fidelity Enhanced Small Cap Core ETF | 0.54% | 108K | $2.5M | +225 (+0.2%) | September 30, 2026 |
| 15 | Meridian Small Cap Growth Legacy | 0.38% | 76K | $1.8M | — | June 30, 2026 |
| 16 | Vanguard Russell 2000 ETF | 0.33% | 65K | $1.5M | +1,580 (+2.5%) | August 31, 2026 |
| 17 | PGIM Jennison Small Company A | 0.32% | 64K | $1.5M | — | August 31, 2026 |
| 18 | Xtrackers MSCI World Swap ETF 1C | 0.28% | 56K | $1.3M | −351 (−0.6%) | December 31, 2025 |
| 19 | Fidelity Extended Market Index | 0.27% | 54K | $1.3M | +369 (+0.7%) | August 31, 2026 |
| 20 | International Biotechnology Ord | 0.26% | 52K | $1.2M | — | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
NGNE insider transactions
latest 3| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-13 | Christine Mikail Cvijic | Sell | $20.81 | 4,045 | $84,176 |
| 2026-03-13 | Stuart Cobb | Sell | $20.81 | 6,797 | $141,446 |
| 2025-05-14 | Stuart Cobb | Sell | $15.15 | 6,797 | $102,975 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
NGNE shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns NGNE
Institutional investors own 97.6% of Neurogene's shares and insiders 6.98%. The largest holder is Samsara BioCapital, LLC with 8.58% of the shares (1.7M), as of June 30, 2026. Among the top 20 institutions, 7 added shares and 8 reduced their stake in the latest filings. Short interest is 29.50% of the float, or 16.10 days of average trading volume. The share count rose 1,449.0% since 2014.
Related: NGNE analyst forecast, NGNE key metrics. See the NGNE stock overview for the latest quote and news.
NGNE ownership FAQ
Who owns the most Neurogene stock?
The largest shareholders of Neurogene are Samsara BioCapital, LLC (8.58%), Casdin Capital, LLC (7.72%), Redmile Group, LLC (7.06%), RTW INVESTMENTS, LLC (6.81%), EcoR1 Capital, LLC (6.35%).
What percentage of Neurogene is owned by institutions?
Institutions hold 97.6% of Neurogene's shares outstanding; insiders hold 6.98%.
Which funds own Neurogene?
The largest fund holders of Neurogene are Vanguard MStar Total Stk Mkt Idx Invest (2.60%), Franklin Biotechnology Discv A(acc)USD (2.05%), iShares Russell 2000 ETF (2.02%), State Street® SPDR® S&P® Biotech ETF (1.34%), T. Rowe Price Small-Cap Stock (1.32%).
What is Neurogene's short interest?
5.0M shares of Neurogene were sold short, 29.50% of the float; at the average daily volume it would take 16.10 days to cover.
Are insiders buying or selling Neurogene?
Of the latest 3 reported insider transactions in Neurogene (since May 14, 2025), 0 were purchases and 3 were sales.
How many shares of Neurogene are outstanding?
Neurogene has 20.0M shares outstanding, of which 11.3M are in the public float.